A phase 1 dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of XL228 administered intravenously to subjects with advanced malignancies.

Trial Profile

A phase 1 dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of XL228 administered intravenously to subjects with advanced malignancies.

Discontinued
Phase of Trial: Phase I

Latest Information Update: 26 Aug 2015

At a glance

  • Drugs XL 228 (Primary)
  • Indications Lymphoma; Multiple myeloma; Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 04 Apr 2011 Planned End Date changed from 1 May 2010 to 1 Jun 2011 as reported by ClinicalTrials.gov.
    • 04 Apr 2011 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
    • 01 Jun 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top